Shares of Johnson & Johnson (JNJ -1.59%) were sliding today as the diversified healthcare company edged past estimates in its fourth-quarter earnings report, but agreed to pay $700 million to settle lawsuits saying that its talc-based baby powder caused cancer. J&J also announced a settlement with the state of Washington over opioid-related claims for $149.5 million and said it had now resolved all pending litigation over the opioid crisis. As of 11:08 a.m. ET, the stock was down 2%. A good, but not good en ...

Johnson & Johnson’s (JNJ) fourth-quarter 2023 earnings came in at $2.29 per share, which beat the Zacks Consensus Estimate of $2.27. Earnings rose 11.7% from the year-ago period.Adjusted earnings exclude intangible amortization and some other special items. Including these items, J&J reported fourth-quarter earnings of $1.70 per share, up 39.3% from the year-ago quarter.Sales of this drug and medical devices giant came in at $21.4 billion, beating the Zacks Consensus Estimate of $21.1 billion by a slight ma ...

Johnson & Johnson on Tuesday said it had reached a tentative settlement to resolve probes by states into whether it misled consumers about the safety of its talc products, which thousands of lawsuits claim can cause cancer.The deal includes 42 states and Washington, DC. The company tentatively agreed to pay about $700 million to settle the states’ claims, according to the Wall Street Journal.“Consistent with the plan we outlined last year, the company continues to pursue several paths to achieve a comprehe ...

For the quarter ended December 2023, Johnson & Johnson (JNJ) reported revenue of $21.4 billion, down 9.8% over the same period last year. EPS came in at $2.29, compared to $2.35 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $21.11 billion, representing a surprise of +1.34%. The company delivered an EPS surprise of +0.88%, with the consensus EPS estimate being $2.27.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall ...

New Jersey-based pharmaceutical giant Johnson & Johnson (NYSE:JNJ) hit top-line expectations in today’s annual earnings call, but slightly undershot with its adjusted earnings results. The company reported a reported 6.5% year-on-year growth in sales of $85.2 billion but the full-year earnings per share (EPS) depicted a different trend, decreasing by 15.3% to $5.20 a share. This decline was primarily due to a special one-time charge incurred in the first quarter. On an adjusted basis, EPS increased by 11.1% ...

Key PointsJohnson & Johnson has solid growth in core segments and reiterated its guidance for the year. The dividend is safe for 2024 and may include another increase this spring. Analysts have trimmed their targets and may cap gains for this stock in the year's first half. 5 stocks we like better than Johnson & JohnsonJohnson & Johnson NYSE: JNJ had a solid quarter in Q4 despite the impacts of the Kenvue spin-off and the deleveraging of COVID-19 sales. However, little has emerged to catalyze the bulls, alt ...

Johnson & Johnson (NYSE: JNJ) just reported its financial results for the fourth quarter that slightly topped Street estimates. Its shares are roughly flat in premarket on Tuesday.Johnson & Johnson’s guidance for fiscal 2024Copy link to sectionThe pharmaceutical giant now forecasts its full-year sales to fall between $87.8 billion and $88.6 billion on up to $10.75 of per-share earnings. Analysts, in comparison, were at $87.9 billion and $10.68 a share, respectively. Joaquin Duato – the chief executive of Jo ...

Johnson & Johnson JNJ, +0.49% said Tuesday it had net earnings of $4.132 billion, or $1.70 a share, for the fourth quarter, up from $3.227 billion, or $1.22 a share, in the year-earlier period. Adjusted per-share earnings came to $2.29, just ahead of the $2.28 FactSet consensus. Sales rose to $21.395 billion from $19.939 billion a year ago, also ahead of the $21.022 billion FactSet consensus. By segment, sales at the company’s innovative medicine business, including COVID vaccines, rose 4.8% to $13.722 bil ...

The stock trading graph of Johnson & Johnson is seen on a smartphone screen.Johnson & Johnson on Tuesday reported fourth-quarter earnings and revenue that narrowly edged out Wall Street's expectations as sales in the company's pharmaceutical and medical devices businesses surged.J&J also provided full-year guidance for 2024, forecasting sales of $87.8 billion to $88.6 billion and adjusted earnings of $10.55 to $10.75 per share. Here's what J&J reported for the fourth quarter compared with what Wall Street w ...

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full year 2023. “Johnson & Johnson’s full year 2023 results reflect the breadth and competitiveness of our business and our relentless focus on delivering for patients,” said Joaquin Duato, Chairman and Chief Executive Officer. “We have entered 2024 from a position of strength, and I am confident in our ability to lead the next wave of health innovation.” Unless otherwise noted, the financia ...